Rexahn Pharmaceuticals, Inc. (NASDAQ:REXN) Sees Significant Growth in Short Interest

Rexahn Pharmaceuticals, Inc. (NASDAQ:REXN) was the target of a significant increase in short interest during the month of December. As of December 31st, there was short interest totalling 115,800 shares, an increase of 11.5% from the December 15th total of 103,900 shares. Approximately 2.9% of the company’s shares are short sold. Based on an average trading volume of 56,300 shares, the short-interest ratio is currently 2.1 days.

Shares of REXN traded up $0.05 during mid-day trading on Thursday, hitting $2.30. The stock had a trading volume of 1,175 shares, compared to its average volume of 42,015. Rexahn Pharmaceuticals has a fifty-two week low of $1.56 and a fifty-two week high of $19.80. The company has a quick ratio of 4.88, a current ratio of 4.88 and a debt-to-equity ratio of 0.01. The company has a market cap of $8.64 million, a PE ratio of -0.44 and a beta of 1.15. The company’s fifty day simple moving average is $1.93 and its two-hundred day simple moving average is $2.67.

Rexahn Pharmaceuticals (NASDAQ:REXN) last released its earnings results on Wednesday, November 6th. The company reported ($0.49) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.54) by $0.05. Equities analysts expect that Rexahn Pharmaceuticals will post -2.26 earnings per share for the current year.

Several brokerages have recently commented on REXN. Zacks Investment Research cut shares of Rexahn Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, October 29th. ValuEngine raised Rexahn Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday, January 3rd.

Rexahn Pharmaceuticals Company Profile

Rexahn Pharmaceuticals, Inc is a clinical stage biopharmaceutical company, which engages in the research and development of oncology therapeutics. Its drug candidates include the following: RX-31171 for pancreatic, bladder, colon, and lung cancer; and RX-5902 for metastatic triple negative breast cancer.

Further Reading: What does cost of debt say about a company’s financial health?

Receive News & Ratings for Rexahn Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rexahn Pharmaceuticals and related companies with's FREE daily email newsletter.